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Abstract
Background—Natural language processing (NLP), an information retrieval technique from text 
documents, accurately identifies quality measures for other endoscopic procedures. There are no 
systematic methods by which to track adherence to quality measures for endoscopic retrograde 
cholangiopancreatography (ERCP), the highest risk endoscopic procedure widely utilized in 
practice.
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Aim—Demonstrate the feasibility of NLP to track adherence to ERCP quality measures across 
individual providers.
Methods—Six providers at a single institution had their ERCPs identified from 2006–2014. 
Quality measures were defined using society guidelines and extracted using a combination of NLP 
and data mining (e.g. ICD-9 CM codes). Validation for each quality measure was performed by 
manual record review. Individualized quality measures were compared across the six providers in 
analyses adjusted and unadjusted for patient age, sex, and race. Quality measures were grouped 
into pre-procedure (5), intra-procedure (6), and post-procedure (2). NLP was evaluated utilizing 
measures of precision and accuracy.
Results—23,674 ERCPs were included in the analysis (average patient age of 52.9±17.8) with 
14,113 (59.6%) women.
Among the thirteen quality measures, precision of NLP ranged from 84–100% with intra-
procedure measures having lower precision (84% for precut sphincterotomy). Accuracy of NLP 
ranged from 90–100% with intra-procedure measures having lower accuracy (90% for pancreatic 
stent placement). One provider did not meet the “appropriate indication” quality measure within 
their individualized 95% confidence interval (78.4 (77.1–79.9)). Documentation of adverse events 
showed the greatest variation (8.8–92.6%).
Conclusion—Use of NLP and data mining allow for individualized tracking of ERCP providers 
for quality metrics without requiring manual medical record review. Incorporation of these tools 
across multiple centers may demonstrate the ability to track ERCP quality measures on a regional 
or national level.
Keywords
Endoscopic retrograde cholangiopancreatography; quality measurement; natural language 
processing
Background
Quality measurement of endoscopy is becoming the standard of care in the United States1–5 
and may influence choice in provider, outcomes, and reimbursement5–7. Endoscopic 
retrograde cholangiopancreatography (ERCP), the highest risk endoscopic procedure in 
widespread practice8 has not been extensively studied for individual, endoscopic-based 
quality measures9. Historically, ERCP quality has been focused on provider or facility 
volume, with higher volumes associated with higher quality as defined by success and 
complication rates after adjusting for procedure indication10, 11. In 2006, the American 
Society for Gastrointestinal Endoscopy (ASGE) and the American College of 
Gastroenterology (ACG) Task Force on Quality Endoscopy provided the first quality 
indicators for ERCP, many based on expert consensus9, and these were subsequently 
updated in 20141.
Similar to colonoscopy, there are challenges in obtaining ERCP-based quality measures due 
to the time intensive nature of manual medical record review. Given this challenge in 
colonoscopy, several studies have demonstrated the feasibility of using natural language 
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processing (NLP) to extract these measures from text documents in the medical record, with 
> 90% accuracy for colonoscopy-specific measures12–16. We hypothesized that NLP could 
be used to track ERCP quality measures accurately and efficiently. If successful, NLP could 
be employed across health systems to monitor ERCP quality and provide feedback to 
providers, administrators, and payers in an effort to show adherence to national benchmarks 
and, if needed, refinement following quality improvement interventions17.
Given the need to systematic measure adherence to quality benchmarks specific to ERCP, 
the primary aim of this study is to measure the precision and accuracy of NLP in 
automatically measuring adherence to ERCP-specific quality measures. The secondary aim 
is to quantify the variation of adherence to quality benchmarks among providers at a single 
institution.17
Methods
After Institutional Review Board (IRB) and Regenstrief Institute data management 
committee approval, we identified ERCP procedure reports and related clinical data from 
1/1/2006 through 7/25/2014.
Data Source
The Indiana Network for Patient Care (INPC)18 is a large regional health information 
exchange that obtains data from 25,000 physicians, 94 hospitals, 110 clinics and surgery 
centers and other healthcare organizations as well as payer data19, 20. The database houses 
more than 4 billion pieces of clinical data with over 160 million text reports and has stored 
data for over 40 years. All ERCP procedure reports as well as ERCP-related radiology 
reports are stored within the INPC and are grouped as the “ERCP” document type and were 
created utilizing a single endoscopy software (Provation® MD; Wolters Kluwer). Clinical 
and payer data sources facilitate pairing ERCP reports with procedure indications 
(International Classification of Diseases, Ninth Revision, Clinical Modification, ICD9-CM) 
and specific maneuvers (Current Procedural Terminology, CPT) codes).
Natural Language Processing System
The Regenstrief Institute has created an Apache Unstructured Information Management 
Applications (UIMA™)21 based NLP system (nDepth) that utilizes open-source applications 
for NLP processing and is released under the Apache license version 2.022. The NLP system 
houses more than 90 million text-based electronic documents from multiple institutions 
throughout Indiana. All documents are indexed within Apache Solr™23 (a method for 
providing distributed indexing with load-balanced querying) for access via Boolean search 
(e.g. “AND”, “OR”, “NOT”). In addition to search, more advanced NLP techniques (e.g. 
negation, regular expressions, and standard terminologies) are also available through the 
system.
Quality Measure Selection
Quality measures were identified based on the 2014 ASGE/ACG Quality Indicators for 
ERCP that were reviewed and endorsed by the American Society of Gastrointestinal 
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Endoscopy (ASGE), the American College of Gastroenterology (ACG), and the American 
Gastroenterological Association (AGA)1. Additional measures (e.g. pre-cut sphincterotomy 
utilized for cannulation) were added from internal discussion with content experts. Measures 
were categorized as: 1) pre-procedure, 2) intra-procedure, and 3) post-procedure. Table 1 
lists the quality indicators and the method by which they were identified. Use of rectal 
indomethacin was not selected as a quality measure since this would have required 
additional programming to interface with pharmacy databases.
Validation of Quality Measures by NLP
We randomly separated the cohort 1:1 into training and testing sets. The training set of 
ERCP reports was used to create NLP algorithms in an iterative fashion (Appendix Figure 
1). The test documents (which were not reviewed during the algorithm development phase) 
were then used to evaluate the ability of the system to accurately determine the expected 
finding. Developing independent training and test sets was done to avoid ‘over-fitting’ the 
algorithm which could reduce external validity.
NLP was utilized to identify ERCP endoscopist and all listed quality measures in Table 1. 
For each quality measure, we randomly selected 50 documents from the training set for 
which the quality measure was identified by NLP and 50 others for which the quality 
measure was not identified. A single expert gastroenterologist (TDI) reviewed all documents 
(different random selection for each quality measure) from the NLP search and assessed true 
positives (TP, those documents that were appropriately identified by the search) and true 
negatives (TN, those documents without the presence of the quality measure by NLP). The 
precision (True positives/50) and accuracy of the NLP search for each quality measure were 
assessed based on these manually reviewed documents. We estimated that 50 documents 
were sufficient for procedure identification given the high prevalence of the measures within 
the dataset as well as our previous experience with NLP validation within endoscopy12, 25. A 
formal power calculation was not performed due to inability to know the percentage of the 
various outcomes a priori.
Statistical analysis was performed to quantify the precision and accuracy of the individual 
quality measures by NLP. Since the entire document set (n = 63,119 ERCP procedures) was 
not manually annotated for a gold standard, a true sensitivity (reports in agreement/positive 
reports by manual review) could not be calculated for this study.
Precision: True positives/Test outcome positives over the 50 reviewed documents.
Accuracy: True positives + True negatives/Total population of 100 reviewed 
documents.
Extraction of non-NLP based Quality Measures (Metrics 1, 6–9, and 12)
Quality measures that did not require text extraction via NLP were extracted/obtained by a 
data manager for the INPC and are listed in Table 1. These quality measures were extracted 
using ICD-9-CM codes and linked to individual ERCP reports using the master medical 
record number and date of procedure.
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Metric “1” (appropriateness of indication) was searched according to ICD-9 CM codes 
based on the multi-society recommendations for appropriate indications1. Appropriate codes 
were identified by rating the indication as highly appropriate or potentially appropriate. 
These codes were rated if they had more than 100 instances of being used in the first or 
second position of billing within 7 days of an ERCP procedure. Additional codes were 
added based on the known appropriate indications despite having less than 100 instances of 
being utilized. ICD9-CM codes for Metric 1 are listed in the appendix. Metric “12” for 
perforation related to the procedure was determined based on ICD-9 CM codes including 
perforation of bile duct (576.3) and perforation of intestine (569.83) within 7 days of ERCP 
procedure. The metric rate was calculated as the number of perforations/the number of total 
ERCP by provider and in aggregate. Metric “13” for significant post-sphincterotomy 
bleeding was determined based on ICD-9 code acute post-hemorrhagic anemia (285.1) 
within 7 days of procedure. The metric rate was # of bleeding events/# of total ERCP by 
provider and in aggregate.
Metrics 6–9 required ICD-9 CM identification prior to NLP analysis. These measures were 
defined using the subgroup of ERCPs performed for choledocholithiasis. Inclusion codes 
were calculus of bile duct (574.3*, 574.4*, 574.5*) with exclusion codes of spasm of 
sphincter of Oddi (576.5), acute pancreatitis (577.1), 577.2 (cyst and pseudocyst of 
pancreas), 577.1 (chronic pancreatitis), 577.8 (other specified disease of pancreas), 751.7 
(anomalies of pancreas), and 157.* (malignant neoplasm of pancreas). We selected 
choledocholithiasis for these metrics since this indication is one of the most common and 
requires biliary cannulation, common bile duct stone extraction, and rates of inadvertent 
pancreatic duct cannulation and injection denote technical proficiency in safely executing 
the procedure.
Comparison of Individual Provider Quality Measures
After each provider (n=6) was identified by NLP, individualized quality metrics were 
extracted. For each provider, patient characteristics including age, gender, and race were 
summarized using mean and standard deviations for continuous variables and frequency and 
proportions for categorical variables. For binary quality metrics, unadjusted rates for each 
provider were calculated using proportions and compared using the Pearson chi-square test. 
Adjusted rates of binary quality metrics were obtained from a logistic regression model that 
controlled for patient characteristics including age, gender, and race. For the number of 
ERCPs performed per year, mean and standard deviation of annual procedural volume were 
calculated over the study period; providers were compared using the ANOVA F-test. All 
statistical analyses were performed using SAS 9.4 (SAS Institute, Cary, NC).
Results
Of 63,119 documents on 15,581 patients that were indexed as an “ERCP” document, 39,440 
were excluded as they were radiology reports or other non-procedure reports. This resulted 
in 23,679 ERCP procedures on 13,299 patients identified by NLP (figure 1). Validation of 
this methodology showed all reviewed documents to be true ERCP procedure reports written 
by an endoscopist (e.g. not a radiology report). Of 23,679 ERCP procedures, 5 were missing 
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patient age, gender, or race and hence were excluded as having incomplete data and not 
available for adjustment. The remaining 23,674 procedures were utilized as the final study 
sample to evaluate the quality measures across the six providers.
The mean age of patients at the time of the procedure was 52.9±17.8 with 59.6% female 
(Appendix Table 1). The majority (75.9%) of patients were Caucasian. Table 2 shows the 
primary outcome of validation including precision and accuracy of the quality measures. 
Precision ranged from 84–100% with intra-procedure measures having lower precisions. 
Accuracy ranged from 90–100% with intra-procedure measures having lower accuracy. We 
excluded seventeen documents post-hoc because the primary provider listed on the note was 
a trainee (n=9) or rarely performed ERCP (n=8).
Table 3 shows the effects of patient characteristics on quality measures based on logistic 
regression for binary quality metrics. Quality metrics with extremely high or extremely low 
prevalence were not examined in the analysis. Age of patient was significantly associated (P 
< 0.05) with QM1 (ERCP performed for an appropriate indication (OR 1.05 (1.03–1.07))), 
QM3 (pre-procedure history and directed physical examination performed and documented 
(OR 1.09 (1.04–1.14))), QM4 (risk for adverse events assessed and documented before 
sedation started (OR 1.03 (1.01–1.06))), and QM11 (precut sphincterotomy for cannulation 
(OR 1.21 (1.16–1.27))), meaning that adherence to these measures increased as patient age 
increased.
Sex of the patient was significantly associated with QM3 (pre-procedure history and directed 
physical examination performed and documented (OR 0.79 (0.67–0.93))), QM6 (deep 
cannulation of the ducts of interest is documented (OR 1.73 (1.05–2.83))), QM8 (pancreatic 
cannulation when not an intended target (OR 1.53 (1.30–1.80))), and QM9 (pancreatic 
injection when not an intended target (OR 1.51 (1.26–1.82))), with higher quality measures 
of QMs 3, X, Y for men and QMs, 6, 8, 9 for women.
Race (white versus other) was significantly associated with QM1 (ERCP performed for an 
appropriate indication (OR 1.11 (1.03–1.19))), QM3 (pre-procedure history and directed 
physical examination are performed and documented (OR 0.83 (0.69–0.99))), QM8 
(pancreatic cannulation when not an intended target (OR 0.78 (0.66–0.92))) and QM9 
(pancreatic injection when not an intended target (OR 0.77 (0.63–0.93)).
Figure 2 shows the unadjusted provider specific quality measurements with 95% confidence 
intervals (CI). Appendix Table 2 shows the adjusted and unadjusted proportions of quality 
measures by provider.
Pre-Procedure Quality Measures
“Appropriate indication” ranged from 78.7–83.3% among the six providers with statistically 
significant variation (P < 0.0001). Provider 6 fell below the 80% quality metric benchmark 
even with the 95% CI (78.7–79.9), results that persisted after adjustment for patient 
characteristics of age, gender, and race. “Informed consent documented” ranged from 99.4–
100%. All providers met the recommended benchmark for this quality metric; no adjustment 
was done for patient factors given the high adherence rate and lack of variation. “Pre-
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procedure H&P documented” ranged from 1.6–3.1%. All six providers failed to meet the 
performance benchmark with minimal change after adjustment for patient factors. There was 
statistical (P = P = 0.0195) but not clinically significant difference among providers. 
“Adverse event risk documented” ranged among the six providers from 8.8–92.6% (P < 
0.0001). All six providers failed to meet the >98% benchmark with or without covariate 
adjustment. Provider 1 (92.6%) and Provider 6 (83.9%) were markedly different then 
Providers 2–5 (8.8–10.9%).
All providers averaged more than 100 ERCPs/year (QM5) with range from 282.7–570.9). 
Appendix Table 1 shows the breakdown of ERCP procedures within the dataset.
Intra-Procedure Quality Measures
The documentation of deep cannulation showed limited clinical variation among the 
providers (97.2–99.4%). All six providers exceeded the >98% quality benchmark within 
their 95% CI. There was a statistically significant difference (P = 0.011) among the six 
providers for this quality measure. “Unsuccessful stone removal < 1 cm” showed no 
variation (99.0–100%) with all six providers meeting the > 98% benchmark. “Pancreatic 
cannulation when not the intended target” ranged from 15.6–26.0% with clinically and 
statistically significant (P < 0.0001) among the six providers. Adjustment for patient factors 
did not markedly change the proportions. The “pancreatic injection when not the intended 
target” ranged from 8.7–22.6%. This was both clinically and statistically significant (P < 
0.0001) among the six providers. Providers 1, 2, and 5 were clinically lower (8.7–11.8%) 
then Providers 3, 4, and 6 (18.9–22.6%). Adjustment for age, gender, and race did not 
markedly affect the metric.
Quality measure 10 (pancreatic stent placement if pancreatic duct cannulated and QM10^ 
(addition of rectal indomethacin to QM10) ranged from 17.9–54.1% and 20.0–54.1% 
respectively. Both metrics showed statistically significant (P =0.002 and P= 0.0009) 
variation among the six providers.
“Precut sphincterotomy for cannulation” ranged from 1.1–4%. There was significant 
variation among the six providers (P < 0.0001). Adjustment for age, gender, and race did not 
markedly affect the metric.
Post-Procedure Quality Measures
Perforation rate among the six providers ranged from 0.1–0.2% with a targeted quality 
measure of 0.2%. Significant bleeding occurred in 0.1–0.2% of patients within 7 days of the 
procedure, well below the 1% cut-off for procedural quality.
DISCUSSION
ERCP is a challenging procedure with high risk for complications and technical failure. The 
risks increase exponentially when the procedure is performed for non-obstructive indications 
(e.g., sphincter of Oddi dysfunction or idiopathic acute pancreatitis). Feedback to 
colonoscopists on their adenoma detection rate (ADR) improves provider performance17 and 
is associated with the subsequent risk of colorectal cancer5. It is plausible that feedback to 
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ERCP providers on their adherence to national recommendations would also improve the 
quality of ERCP services provided. The primary objective of this study was to develop a 
feasible method to track quality metrics in ERCP. An example of a stoplight report card is 
shown in Figure 3. Utilizing an existing, open-source based NLP system; we extracted 
quality measures over an 8.5-year period and compared them across individual providers and 
to society guidelines. This work is the first attempt to assess ERCP quality measures using 
NLP, and supports the feasibility of applying these techniques to larger datasets across 
multiple health care systems.
In our study we demonstrate clinically significant variation (e.g. rate of pancreatic 
cannulation when not the intended target) among providers, even in a highly skilled group of 
endoscopists at a single referral center (>9% variation). Given that one of the high risks for 
ERCP is development of post-ERCP pancreatitis, this may be a high-impact quality metric 
even among high-volume providers of ERCP. This knowledge may guide quality 
improvement projects to enhance appropriate documentation and identify providers who are 
not meeting society-endorsed benchmarks. While many of the measures (e.g. document pre-
procedure H&P) may not reflect quality as these are often done externally to the report, they 
are contained within the quality tracking measurements for all endoscopic procedures.
The study has several limitations. First, the sample is restricted to ERCPs performed at a 
regional referral center. While this high volume unit does not reflect the general patient 
population, adherence to quality measures should apply to all ERCP providers. Furthermore, 
this study seeks to develop and validate a feasible method for assessing ERCP quality 
measures, not to report compliance with society guidelines.
A second limitation is that a single endoscopy software (Provation® MD; Wolters Kluwer) 
was utilized during the study period. This greatly enhances the ability for text mining and 
natural language processing to accurately detect specific concepts (e.g. 100% accuracy for 
providers). However, our group has shown that this technique can be applied to other 
institutions and accurately measure variables despite different methods for text document 
entry (e.g. dictation and endoscopy software)16. We also made assumptions about ICD-9-
CM coding in relation to the procedure. This can be seen with the post-sphincterotomy 
bleeding rate allowing for 7 days after the procedure for any event associated with a specific 
ICD-9-CM code (285.1). With this assumption we may pick up non-ERCP related bleeding 
and/or bleeding not due to sphincterotomy. Additional ICD-9-CM coding such as 578.9 (GI 
bleeding) and 998.11 (hemorrhage complicating a procedure) might be utilized in the future 
to expand the identification of delayed complications.
Adjustment was done on multiple measures for this study; however, indication was not 
utilized for statistical adjustment and may significantly impact intra-procedure and post-
procedure quality measures. Grouping ICD-9 CM codes into biliary, pancreatic, or dual 
indications may allow for adjustment in the future.
Last, when we compared our identification of ERCP documents by NLP to those produced 
by the endowriter software we noticed a difference of 4.1%. While this is a relatively small 
discrepancy, there are multiple potential explanations for this discrepancy. First, NLP may 
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not have correctly identified the documents as ERCP procedure reports from the 63,119 
documents that were indexed as ERCP in the health information exchange. Second, the 
documents derived from the endowriter may not have been completely transmitted to the 
health information exchange, or have been duplicates. Last, the procedure report may have 
been filed under a different document type (e.g. operative report). Still, a discrepancy rate of 
4.1% is low and would be unlikely to impact these observations.
Conclusion
Overall, our study shows that NLP and data mining are capable of tracking adherence to 
ERCP-specific quality measures. Among six providers of ERCP at a single academic 
referral center there was significant variation in selected quality measures. The next step is 
to prove the external validity of this technique by assessing these measures using data from 
multiple institutions that utilize different types of electronic medical records.
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Appendix
ICD-9 CM Inclusion for Metric 1
Appropriate Indication codes included; calculus of bile duct (574.3*, 574.4*, 574.5*), 
cholangitis (576.1), obstruction of bile duct (576.2), fistula of bile duct (576.4), spasm of 
sphincter of Oddi (576.5), other specified disorders of biliary tract (576.8), acute pancreatitis 
(577.1), 577.2 (cyst and pseudocyst of pancreas), 577.1 (chronic pancreatitis), 577.8 (other 
specified disease of pancreas), 751.7 (anomalies of pancreas), 157.* (malignant neoplasm of 
pancreas), 156.* (malignant neoplasm of gallbladder and extrahepatic bile ducts), and 155.* 
(malignant neoplasm of liver and intrahepatic bile ducts). All codes were linked to an 
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appropriate ERCP related CPT code within the data set. The metric rate was number of 
appropriately identified ERCP/number of total ERCP by provider and in aggregate.
ICD-9 CM Inclusion for Metric 6–9
Inclusion codes were calculus of bile duct (574.3*, 574.4*, 574.5*) with exclusion codes of 
spasm of sphincter of Oddi (576.5), acute pancreatitis (577.1), 577.2 (cyst and pseudocyst of 
pancreas), 577.1 (chronic pancreatitis), 577.8 (other specified disease of pancreas), 751.7 
(anomalies of pancreas), and 157.* (malignant neoplasm of pancreas).
Appendix Figure 1. 
Overview of the phenotype development process for unstructured data
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Appendix Table 1
Breakdown of ERCP procedures within dataset.
Provider # of ERCP Per Year Rate (Std) # of Patients Age (Std) Female White
Provider 1 1696 282.7 (113.3) 1060 53.7 (17.6) 991 (58.5%) 1266 (74.6%)
Provider 2 5133 570.4 (194.5) 3084 51.9 (18.0) 3174 (61.8%) 3946 (76.9%)
Provider 3 4455 495.3 (192.9) 3103 51.6 (17.0) 2812 (63.1%) 3460 (77.7%)
Provider 4 2680 297.9 (83.7) 1804 56.3 (17.3) 1497 (55.9%) 1998 (74.6%)
Provider 5 5138 570.9 (157.9) 2507 52.9 (18.1) 3025 (58.9%) 3920 (76.3%)
Provider 6 4572 508.0 (137.5) 2935 52.8 (17.9) 2614 (57.3%) 3386 (74.1%)
P Value < 0.001 Not felt to be clinically significant
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Appendix Table 2
Adjusted and unadjusted proportions of quality measures by provider (excluding measure 
#5).
Quality Measure Method Provider Numerator Denominator
Mean % (95% 
CI) P Value
Frequency with which 
endoscopy is performed 
for an appropriate 
indication (QM1)
Adjusted Provider 1 . . 79.5 (77.4–81.3) <.0001
Provider 2 . . 79.6 (78.5–80.8)
Provider 3 . . 80.7 (79.4–81.9)
Provider 4 . . 78.8 (77.2–80.4)
Provider 5 . . 83.0 (81.9–84.1)
Provider 6 . . 78.4 (77.1–79.6)
Unadjusted Provider 1 1354 1696 79.8 (77.9–81.7) <.0001
Provider 2 4099 5134 79.8 (78.7–80.9)
Provider 3 3603 4458 80.8 (79.7–82.0)
Provider 4 2129 2681 79.4 (77.9–80.9)
Provider 5 4280 5138 83.3 (82.3–84.3)
Provider 6 3600 4572 78.7 (77.6–79.9)
Frequency with which 
informed consent is 
obtained and fully 
documented (QM2)
Unadjusted Provider 1 1696 1696 100 (99.8–100) *
Provider 2 5134 5134 100 (99.9–100)
Provider 3 4432 4458 99.4 99.1–99.6)
Provider 4 2679 2681 99.9 (99.7–100)
Provider 5 5137 5138 100 (99.9–100)
Provider 6 4570 4572 100 (99.8–100)
Frequency with which 
pre- procedure history 
and directed physical 
examination are 
performed and 
documented (QM3)
Adjusted Provider 1 . . 1.7 (1.2–2.4) 0.0223
Provider 2 . . 2.9 (2.4–3.4)
Provider 3 . . 3.3 (2.8–3.9)
Provider 4 . . 3.0 (2.4–3.7)
Provider 5 . . 2.5 (2.1–3.0)
Provider 6 . . 2.8 (2.3–3.3)
Unadjusted Provider 1 27 1696 1.6 (1.0–2.2) 0.0195
Provider 2 139 5134 2.7 (2.3–3.2)
Provider 3 139 4458 3.1 (2.6–3.6)
Provider 4 79 2681 2.9 (2.3–3.6)
Provider 5 123 5138 2.4 (2.0–2.8)
Provider 6 120 4572 2.6 (2.2–3.1)
Frequency with which 
risk for adverse events is 
assessed and 
documented before 
sedation is started 
(QM4)
Adjusted Provider 1 . . 92.5 (91.2–93.7) <.0001
Provider 2 . . 9.0 (8.2–9.8)
Provider 3 . . 10.3 (9.4–11.3)
Provider 4 . . 10.8 (9.6–12.0)
Provider 5 . . 8.8 (8.0–9.7)
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Quality Measure Method Provider Numerator Denominator
Mean % (95% 
CI) P Value
Provider 6 . . 83.9 (82.8–85.0)
Unadjusted Provider 1 1570 1696 92.6 (91.3–93.8) <.0001
Provider 2 459 5134 8.9 (8.2–9.7)
Provider 3 460 4458 10.3 (9.4–11.2)
Provider 4 292 2681 10.9 (9.7–12.1)
Provider 5 452 5138 8.8 (8.0–9.6)
Provider 6 3835 4572 83.9 (82.8–84.9)
Frequency with which 
deep cannulation of the 
ducts of interest is 
documented (QM6)
Adjusted Provider 1 . . 97.2 (94.1–98.7) 0.0219
Provider 2 . . 99.4 (98.6–99.7)
Provider 3 . . 97.1 (95.3–98.3)
Provider 4 . . 99.1 (97.4–99.7)
Provider 5 . . 98.2 (97.0–98.9)
Provider 6 . . 98.0 (96.9–98.8)
Unadjusted Provider 1 225 231 97.4 (94.4–99.0) 0.0107
Provider 2 892 897 99.4 (98.7–99.8)
Provider 3 516 531 97.2 (95.4–98.4)
Provider 4 378 381 99.2 (97.7–99.8)
Provider 5 835 850 98.2 (97.1–99.0)
Provider 6 905 923 98.0 (96.9–98.8)
Frequency with which 
common bile duct 
stones <1 cm in patients 
with normal bile duct 
anatomy are extracted 
successfully and 
documented (QM7)
Unadjusted Provider 1 229 231 99.1 (96.9–99.9) *
Provider 2 896 897 99.9 (99.4–100)
Provider 3 526 531 99.1 (97.8–99.7)
Provider 4 377 381 99.0 (97.3–99.7)
Provider 5 847 850 99.6 (99.0–99.9)
Provider 6 923 923 100 (99.6–100)
Frequency of pancreatic 
cannulation when not an 
intended target (QM8)
Adjusted Provider 1 . . 15.7 (11.5–21%) <.0001
Provider 2 . . 16.9 (14.5–19.5)
Provider 3 . . 27.7 (24.0–31.8)
Provider 4 . . 26.0 (21.8–30.8)
Provider 5 . . 20.3 (17.6–23.2)
Provider 6 . . 24.5 (21.7–27.5)
Unadjusted Provider 1 36 231 15.6 (10.9–20.3) <.0001
Provider 2 148 897 16.5 (14.1–18.9)
Provider 3 145 531 27.3 (23.5–31.1)
Provider 4 99 381 26.0 (21.6–30.4)
Provider 5 170 850 20.0 (17.3–22.7)
Provider 6 220 923 23.8 (21.1–26.6)
Frequency of pancreatic 
injection when not an 
intended target (QM9)
Adjusted Provider 1 . . 8.8 (5.7–13.2) <.0001
Provider 2 . . 12.1 (10.1–14.5)
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Quality Measure Method Provider Numerator Denominator
Mean % (95% 
CI) P Value
Provider 3 . . 22.9 (19.4–26.8)
Provider 4 . . 19.0 (15.3–23.4)
Provider 5 . . 10.8 (8.8–13.1)
Provider 6 . . 20.8 (18.2–23.7)
Unadjusted Provider 1 20 231 8.7 (5.0–12.3) <.0001
Provider 2 106 897 11.8 (9.7–13.9)
Provider 3 120 531 22.6 (19.0–26.2)
Provider 4 72 381 18.9 (15.0–22.8)
Provider 5 90 850 10.6 (8.5–12.7)
Provider 6 187 923 20.3 (17.7–22.9)
Frequency of pancreatic 
stent placement if 
pancreatic duct 
cannulated (QM10)
Adjusted Provider 1 . . 52.7 (36.7–68.2) 0.0012
Provider 2 . . 17.8 (12.4–24.8)
Provider 3 . . 21.0 (15.2–28.3)
Provider 4 . . 18.7 (12.2–27.6)
Provider 5 . . 23.4 (17.5–30.5)
Provider 6 . . 20.7 (15.7–26.6)
Unadjusted Provider 1 20 37 54.1 (38.0–70.1) 0.0002
Provider 2 27 151 17.9 (11.8–24.0)
Provider 3 34 160 21.3 (14.9–27.6)
Provider 4 19 100 19.0 (11.3–26.7)
Provider 5 40 170 23.5 (17.2–29.9)
Provider 6 46 221 20.8 (15.5–26.2)
Frequency of pancreatic 
stent placement and/or 
indomethacin given if 
pancreatic duct 
cannulated (QM10^)
Adjusted Provider 1 . . 53.1 (37.1–68.5) 0.0020
Provider 2 . . 21.5 (15.6–28.8)
Provider 3 . . 23.1 (17.1–30.5)
Provider 4 . . 19.8 (13.1–28.8)
Provider 5 . . 29.5 (23.1–37.0)
Provider 6 . . 29.4 (23.6–35.9)
Unadjusted Provider 1 20 37 54.1 (38.0–70.1) 0.0009
Provider 2 33 151 21.9 (15.3–28.4)
Provider 3 38 160 23.8 (17.2–30.3)
Provider 4 20 100 20.0 (12.2–27.8)
Provider 5 51 170 30.0 (23.1–36.9)
Provider 6 66 221 29.9 (23.8–35.9)
Frequency of precut 
sphincterotomy for 
cannulation
Adjusted Provider 1 . . 2.6 (2.0–3.5) <.0001
Provider 2 . . 3.6 (3.1–4.2)
Provider 3 . . 3.9 (3.3–4.5)
Provider 4 . . 2.2 (1.7–2.8)
Provider 5 . . 2.4 (2.0–2.9)
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Quality Measure Method Provider Numerator Denominator
Mean % (95% 
CI) P Value
Provider 6 . . 1.1 (0.8–1.4)
Unadjusted Provider 1 47 1696 2.8 (2.0–3.6) <.0001
Provider 2 193 5134 3.8 (3.2–4.3)
Provider 3 177 4458 4.0 (3.4–4.5)
Provider 4 65 2681 2.4 (1.8–3.0)
Provider 5 130 5138 2.5 (2.1–3.0)
Provider 6 52 4572 1.1 (0.8–1.4)
Frequency of 
perforation due to 
ERCP (within 7 days)
Unadjusted Provider 1 3 1696 0.2 (0.0–0.5) *
Provider 2 8 5134 0.2 (0.1–0.3)
Provider 3 5 4458 0.1 (0.0–0.3)
Provider 4 4 2681 0.1 (0.0–0.4)
Provider 5 5 5138 0.1 (0.0–0.2)
Provider 6 3 4572 0.1 (0.0–0.2)
Rate of clinically 
significant hemorrhage 
after ERCP with or 
without sphincterotomy 
(within 7 days)
Unadjusted Provider 1 4 1696 0.2 (0.1–0.6) *
Provider 2 8 5134 0.2 (0.1–0.3)
Provider 3 1 4458 0.0 (0.0–0.1)
Provider 4 4 2681 0.1 (0.0–0.4)
Provider 5 11 5138 0.2 (0.1–0.4)
Provider 6 4 4572 0.1 (0.0–0.2)
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Figure 1. 
Flow chart for study.
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Figure 2. 
Unadjusted provider specific quality measurements for ERCP with 95% confidence 
intervals.
• QM1 = endoscopy is performed for an appropriate indication
• QM2 = informed consent is obtained and fully documented
• QM3 = pre-procedure history and directed physical examination are performed 
and documented
• QM4 = risk for adverse events is assessed and documented before sedation is 
started
• QM5 = Volume of ERCPs performed per year by endoscopist
• QM6 = deep cannulation of the ducts of interest is documented*
• QM7 = common bile duct stones <1 cm in patients with normal bile duct 
anatomy are extracted successfully and documented
• QM8 = pancreatic cannulation when not an intended target*
• QM9 = pancreatic injection when not an intended target*
• QM10 = pancreatic stent placement if pancreatic duct cannulated
• QM11 = precut sphincterotomy for cannulation
• QM12 = perforation due to ERCP (within 7 days)
• QM13 = Rate of clinically significant hemorrhage after ERCP with or without 
sphincterotomy (within 7 days)
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Figure 3. 
Adjusted provider specific quality measurements for ERCP with 95% confidence intervals.
• QM1 = endoscopy is performed for an appropriate indication
• QM3 = pre-procedure history and directed physical examination are performed 
and documented
• QM4 = risk for adverse events is assessed and documented before sedation is 
started
• QM6 = deep cannulation of the ducts of interest is documented
• QM8 = pancreatic cannulation when not an intended target
• QM9 = pancreatic injection when not an intended target
• QM10 = pancreatic stent placement if pancreatic duct cannulated
• QM11 = precut sphincterotomy for cannulation
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Figure 4. 
Example provider quality report card based on Provider 1 overall measure. Green is for 
being above the benchmark including 95% CI. Yellow includes the benchmark in the 95% 
CI. Red is below the benchmark including the 95% CI.
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